tiprankstipranks
Advertisement
Advertisement

RGNX Stock Latest News

Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
The FlyPrivate Markets: Cursor in talks for $2B, Blue Energy secures $380M
8d ago
BA
BE
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
18d ago
DYN
RNA
Shareholders Sue RGNX Over Gene Therapy Study Claims
PremiumMarket News
Shareholders Sue RGNX Over Gene Therapy Study Claims
1M ago
RGNX
RegenXBio Reaches Settlement with GSK Over License Fees
PremiumCompany Announcements
RegenXBio Reaches Settlement with GSK Over License Fees
1M ago
8K
RGNX
REGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
PremiumClass Action
REGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
2M ago
RGNX
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
PremiumThe FlyRegenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
2M ago
RGNX
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
Premium
The Fly
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
2M ago
RGNX
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
2M ago
AZN
BMY
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
PremiumCompany Announcements
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
2M ago
RGNX
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
PremiumMarket News
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
2M ago
MGX
HELP
RegenXBio Earnings Call Balances Gene Therapy Risks
PremiumCompany Announcements
RegenXBio Earnings Call Balances Gene Therapy Risks
2M ago
RGNX
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
PremiumThe Fly
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
2M ago
RGNX
RegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
PremiumRatingsRegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
2M ago
RGNX
Regenxbio price target lowered to $42 from $45 at Stifel
Premium
The Fly
Regenxbio price target lowered to $42 from $45 at Stifel
2M ago
RGNX
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
Premium
The Fly
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
2M ago
RGNX
FDA review process for accelerated approval narrows, less predictable, WSJ says
PremiumThe Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
2M ago
CAPR
IRON
RGNX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
RGNX Earnings this Week: How Will it Perform?
2M ago
RGNX
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
PremiumClass Action
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
2M ago
RGNX
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
PremiumClass Action
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
2M ago
RGNX
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
PremiumCompany AnnouncementsRegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
2M ago
RGNX
Stifel says uniQure ‘understandably’ under pressure on Makary comments
Premium
The Fly
Stifel says uniQure ‘understandably’ under pressure on Makary comments
2M ago
QURE
RGNX
Why Is UniQure Stock Down 30% Today?
Premium
Market News
Why Is UniQure Stock Down 30% Today?
2M ago
QURE
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >